{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:14:41Z","timestamp":1792206881795,"version":"4.4.0"},"reference-count":82,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2016,5,19]],"date-time":"2016-05-19T00:00:00Z","timestamp":1463616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0155869","type":"journal-article","created":{"date-parts":[[2016,5,20]],"date-time":"2016-05-20T01:11:20Z","timestamp":1463706680000},"page":"e0155869","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":109,"title":["Geno2pheno[HCV] \u2013 A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents"],"prefix":"10.1371","volume":"11","author":[{"given":"Prabhav","family":"Kalaghatgi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Sikorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Knops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleta","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Heger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Neumann-Fraune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Beggel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Timm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauke","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Obermeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Bartenschlager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lengauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,5,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"K Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","article-title":"Hepatocellular carcinoma","volume":"365","author":"HB El-Serag","year":"2011","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.3748\/wjg.v20.i11.2876","article-title":"Hepatitis C-related liver cirrhosis\u2014strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality","volume":"20","author":"N Toshikuni","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrmicro3046","article-title":"The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection","volume":"11","author":"R Bartenschlager","year":"2013","journal-title":"Nat Rev Microbiol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1073\/pnas.1203110110","article-title":"Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life","volume":"110","author":"J Guedj","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"AU Neumann","year":"1998","journal-title":"Science"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1073\/pnas.88.8.3392","article-title":"Nucleotide sequence and mutation rate of the H strain of hepatitis C virus","volume":"88","author":"N Ogata","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1053\/j.gastro.2007.03.035","article-title":"Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy","volume":"132","author":"G Lutchman","year":"2007","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hep.20819","article-title":"Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes","volume":"42","author":"P Simmonds","year":"2005","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"DB Smith","year":"2014","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"ref11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/liv.12423","article-title":"HCV direct-acting antiviral agents: the best interferon-free combinations","volume":"34","author":"R Schinazi","year":"2014","journal-title":"Liver Int"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/HMER.S55864","article-title":"Interferon-free combination therapies for the treatment of hepatitis C: current insights","volume":"7","author":"JA Holmes","year":"2015","journal-title":"Hepat Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","article-title":"From non-A, non-B hepatitis to hepatitis C virus cure","volume":"62","author":"JM Pawlotsky","year":"2015","journal-title":"J Hepatol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL Recommendations on Treatment of Hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"ref15","unstructured":"AASLD-IDSA (2015) HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofv043","article-title":"Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors","volume":"2","author":"A De Luca","year":"2015","journal-title":"Open Forum Infectious Diseases"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1128\/AAC.01598-08","article-title":"GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796","volume":"53","author":"MF McCown","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e39652","DOI":"10.1371\/journal.pone.0039652","article-title":"HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors","volume":"7","author":"V Cento","year":"2012","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus","volume":"53","author":"JM Pawlotsky","year":"2011","journal-title":"Hepatology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/hep.26388","article-title":"Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir","volume":"58","author":"F McPhee","year":"2013","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2012.11.012","article-title":"Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir","volume":"58","author":"Y Karino","year":"2013","journal-title":"J Hepatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"E115","DOI":"10.1111\/hepr.12474","article-title":"Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy","volume":"45","author":"J Itakura","year":"2015","journal-title":"Hepatol Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1128\/AAC.02494-12","article-title":"Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir","volume":"57","author":"C Wang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/cit226","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials","volume":"57","author":"JC Sullivan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.virol.2013.06.029","article-title":"Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies","volume":"444","author":"RJ Barnard","year":"2013","journal-title":"Virology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000361076","article-title":"Hepatitis B virus drug resistance tools: one sequence, two predictions","volume":"57","author":"M Neumann-Fraune","year":"2014","journal-title":"Intervirology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1093\/nar\/gkg575","article-title":"Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes","volume":"31","author":"N Beerenwinkel","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/nbt1371","article-title":"Bioinformatics prediction of HIV coreceptor usage","volume":"25","author":"T Lengauer","year":"2007","journal-title":"Nat Biotechnol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1365-2893.2010.01342.x","article-title":"Evidence for separation of HCV subtype 1a into two distinct clades","volume":"18","author":"BE Pickett","year":"2011","journal-title":"J Viral Hepat"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"17508","DOI":"10.1074\/jbc.M313020200","article-title":"In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms","volume":"279","author":"C Lin","year":"2004","journal-title":"J Biol Chem"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"36784","DOI":"10.1074\/jbc.M506462200","article-title":"In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061","volume":"280","author":"C Lin","year":"2005","journal-title":"J Biol Chem"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"C Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1128\/AAC.01149-07","article-title":"Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system","volume":"52","author":"Y He","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.antiviral.2007.11.010","article-title":"Characterization of resistance mutations against HCV ketoamide protease inhibitors","volume":"77","author":"X Tong","year":"2008","journal-title":"Antiviral Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1128\/AAC.00863-07","article-title":"Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease","volume":"52","author":"Y Zhou","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/hep.23192","article-title":"Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients","volume":"50","author":"S Susser","year":"2009","journal-title":"Hepatology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1128\/AAC.00777-10","article-title":"Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors","volume":"54","author":"A Bae","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"O Lenz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"e34372","DOI":"10.1371\/journal.pone.0034372","article-title":"Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials","volume":"7","author":"TL Kieffer","year":"2012","journal-title":"PLoS One"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/AAC.05166-11","article-title":"In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335","volume":"56","author":"L Lagac\u00e9","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.2146\/ajhp110500","article-title":"Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection","volume":"69","author":"JT Lam","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1128\/AAC.01186-12","article-title":"Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)","volume":"56","author":"F McPhee","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref43","doi-asserted-by":"crossref","DOI":"10.1055\/s-0032-1323987","article-title":"Ultratiefe Pyrosequenz-Analyse (UDPS) von neu beschriebenen seltenen Resistenzvarianten der Hepatitis C Virus NS3 Protease bei Patienten, die mit Telaprevir oder Boceprevir behandelt wurden","volume":"50","author":"S Susser","year":"2012","journal-title":"Z Gastroenterol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1128\/AAC.05977-11","article-title":"Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052","volume":"56","author":"C Wang","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref45","first-page":"139","article-title":"Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection","volume":"20","author":"DL Wyles","year":"2012","journal-title":"Top Antivir Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/cmdc.201300343","article-title":"Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity","volume":"8","author":"CA Coburn","year":"2013","journal-title":"ChemMedChem"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.12.020","article-title":"Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors","volume":"57","author":"D Hernandez","year":"2013","journal-title":"J Clin Virol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"E Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"ref49","unstructured":"Lawitz E, Poordad F, Membreno FE, Hyland H, Ding X, Hebner C, et al. Once Daily Sofosbuvir\/Ledipasvir Fixed Dose Combination with or without Ribavirin Resulted in \u226595% Sustained Virologic Response In Patients with HCV Genotype 1, Including Patients with Cirrhosis: the LONESTAR trial; 2013 November 1\u20135, 2013; Washington, DC, USA. pp. Abstract 215."},{"key":"ref50","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jhep.2012.10.028","article-title":"Virologic response and characterisation of HCV genotype 2\u20136 in patients receiving TMC435 monotherapy (study TMC435-C202)","volume":"58","author":"O Lenz","year":"2013","journal-title":"J Hepatol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1128\/AAC.01874-12","article-title":"In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A","volume":"57","author":"C Wang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1128\/AAC.02193-12","article-title":"Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885","volume":"57","author":"KA Wong","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/cid\/ciu696","article-title":"Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon\/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection","volume":"59","author":"AY Howe","year":"2014","journal-title":"Clin Infect Dis"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2013.10.019","article-title":"Randomized trial of daclatasvir and asunaprevir with or without PegIFN\/RBV for hepatitis C virus genotype 1 null responders","volume":"60","author":"AS Lok","year":"2014","journal-title":"J Hepatol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3851\/IMP2729","article-title":"Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b","volume":"19","author":"F McPhee","year":"2014","journal-title":"Antivir Ther"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1128\/AAC.02068-13","article-title":"Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin","volume":"58","author":"E Murakami","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/jit562","article-title":"In vivo emergence of a novel mutant L159F\/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir","volume":"209","author":"X Tong","year":"2014","journal-title":"J Infect Dis"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","article-title":"Infrequent development of resistance in genotype 1\u20136 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials","volume":"59","author":"ES Svarovskaia","year":"2014","journal-title":"Clin Infect Dis"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"S Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.3390\/v7102876","article-title":"HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy","volume":"7","author":"K Chayama","year":"2015","journal-title":"Viruses"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","article-title":"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir","volume":"61","author":"EF Donaldson","year":"2015","journal-title":"Hepatology"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1128\/AAC.01953-15","article-title":"Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance","volume":"59","author":"SB Jensen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1128\/AAC.04619-14","article-title":"In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor","volume":"59","author":"W Kati","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.04226-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A","volume":"59","author":"P Krishnan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s12325-015-0221-5","article-title":"High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms","volume":"32","author":"F McPhee","year":"2015","journal-title":"Adv Ther"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jama.2015.1373","article-title":"Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection","volume":"313","author":"A Osinusi","year":"2015","journal-title":"JAMA"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/AAC.04227-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3\/4A protease inhibitor ABT-450","volume":"59","author":"T Pilot-Matias","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1128\/AAC.01229-15","article-title":"Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir\/Ritonavir","volume":"59","author":"G Schnell","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref70","unstructured":"EMA DAKLINZA: SUMMARY OF PRODUCT CHARACTERISTICS. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003768\/WC500172848.pdf\" xlink:type=\"simple\">http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003768\/WC500172848.pdf<\/ext-link>, Latest accessed: Dez 8, 2015"},{"key":"ref71","unstructured":"EMA EXVIERA: SUMMARY OF PRODUCT CHARACTERISTICS. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003837\/WC500182233.pdf\" xlink:type=\"simple\">http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003837\/WC500182233.pdf<\/ext-link>, Latest accessed: Dez 8, 2015"},{"key":"ref72","unstructured":"EMA VIEKIRAX: SUMMARY OF PRODUCT CHARACTERISTICS. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003839\/WC500183997.pdf\" xlink:type=\"simple\">http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003839\/WC500183997.pdf<\/ext-link>, Latest accessed: Dez 8, 2015"},{"key":"ref73","unstructured":"EMA HARVONI: SUMMARY OF PRODUCT CHARACTERISTICS. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003850\/WC500177995.pdf\" xlink:type=\"simple\">http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003850\/WC500177995.pdf<\/ext-link>, Latest accessed: Dez 8, 2015"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/bioinformatics\/bth485","article-title":"The Los Alamos HCV Sequence Database","volume":"21","author":"C Kuiken","year":"2005","journal-title":"Bioinformatics"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.antiviral.2008.11.002","article-title":"Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates","volume":"81","author":"X Qi","year":"2009","journal-title":"Antiviral Res"},{"key":"ref76","article-title":"Prediction of HIV-1 coreceptor usage (tropism) by sequence analysis using a genotypic approach","author":"S Sierra","year":"2011","journal-title":"J Vis Exp"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"12047","DOI":"10.1128\/JVI.75.24.12047-12057.2001","article-title":"Sequences in the 5&apos; nontranslated region of hepatitis C virus required for RNA replication","volume":"75","author":"P Friebe","year":"2001","journal-title":"J Virol"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1128\/JVI.02177-10","article-title":"A comprehensive structure-function comparison of hepatitis C virus strain JFH1 and J6 polymerases reveals a key residue stimulating replication in cell culture across genotypes","volume":"85","author":"M Schmitt","year":"2011","journal-title":"J Virol"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2014.11.032","article-title":"Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in Phase IIb\/III studies","volume":"62","author":"O Lenz","year":"2015","journal-title":"J Hepatol"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(14)60009-X","article-title":"Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 prior null responders with metavir F0-2: Cosmos study subgroup analysis","volume":"60","author":"M Sulkowski","year":"2014","journal-title":"J Hepatol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"S524","DOI":"10.1016\/S0168-8278(14)61460-4","article-title":"Simeprevir plus sofosbuvir with\/without ribavirin in HCV genotype 1 prior null-responder\/treatment-naive patients (Cosmos study): primary endpoint (SVR12) results in patients with metavir F3-4 (Cohort 2)","volume":"60","author":"E Lawitz","year":"2014","journal-title":"J Hepatol"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","article-title":"Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study","volume":"58","author":"MW Fried","year":"2013","journal-title":"Hepatology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0155869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T08:33:48Z","timestamp":1589013228000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0155869"}},"subtitle":[],"editor":[{"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,5,19]]},"references-count":82,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0155869","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,19]]}}}